Comment
doi: 10.1016/j.molcel.2010.01.010.
WT1 the oncogene: a tale of death and HtrA
Affiliations
- PMID: 20122396
- DOI: 10.1016/j.molcel.2010.01.010
Item in Clipboard
Comment
WT1 the oncogene: a tale of death and HtrA
Mol Cell.
.
Free article
Abstract
Here, Hartkamp et al. (2010) identify WT1 as a novel bona fide substrate of the HtrA2/Omi mitochondrial protease and show that this reaction modulates WT1 antiapoptotic activity under cytotoxic stress. This supports an oncogenic function for WT1, with implications for novel chemotherapeutic avenues.
Copyright 2010 Elsevier Inc. All rights reserved.
Comment on
-
The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.Mol Cell. 2010 Jan 29;37(2):159-71. doi: 10.1016/j.molcel.2009.12.023. Mol Cell. 2010. PMID: 20122399 Free PMC article.
Similar articles
-
HtrA2, taming the oncogenic activities of WT1.Cell Cycle. 2010 Jul 1;9(13):2508-14. doi: 10.4161/cc.9.13.12060. Cell Cycle. 2010. PMID: 20543571 Free PMC article.
-
The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.Mol Cell. 2010 Jan 29;37(2):159-71. doi: 10.1016/j.molcel.2009.12.023. Mol Cell. 2010. PMID: 20122399 Free PMC article.
-
THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death.Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H643-53. doi: 10.1152/ajpheart.00234.2009. Epub 2009 Jun 5. Am J Physiol Heart Circ Physiol. 2009. PMID: 19502560 Free PMC article.
-
[Mitochondrial serine protease Omi/HtrA2 and apoptosis].Sheng Li Ke Xue Jin Zhan. 2006 Jul;37(3):285-8. Sheng Li Ke Xue Jin Zhan. 2006. PMID: 17009747 Review. Chinese. No abstract available.
-
The mitochondrial serine protease HtrA2/Omi: an overview.Cell Death Differ. 2008 Mar;15(3):453-60. doi: 10.1038/sj.cdd.4402291. Epub 2008 Jan 4. Cell Death Differ. 2008. PMID: 18174901 Review.
Cited by
-
RNA Sequencing Identifies WT1 Overexpression as a Predictor of Poor Outcomes in Acute Myeloid Leukemia.Cancers (Basel). 2025 May 29;17(11):1818. doi: 10.3390/cancers17111818. Cancers (Basel). 2025. PMID: 40507300 Free PMC article.
-
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.J Transl Med. 2020 Jun 24;18(1):254. doi: 10.1186/s12967-020-02384-y. J Transl Med. 2020. PMID: 32580769 Free PMC article.
-
HtrA2, taming the oncogenic activities of WT1.Cell Cycle. 2010 Jul 1;9(13):2508-14. doi: 10.4161/cc.9.13.12060. Cell Cycle. 2010. PMID: 20543571 Free PMC article.
-
Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.Br J Haematol. 2024 Jul;205(1):207-219. doi: 10.1111/bjh.19563. Epub 2024 Jun 12. Br J Haematol. 2024. PMID: 38867543 Free PMC article.
-
Prognostic impact of peripheral blood Wilms' tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis.Leuk Res Rep. 2020 Dec 8;15:100231. doi: 10.1016/j.lrr.2020.100231. eCollection 2021. Leuk Res Rep. 2020. PMID: 33354513 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
